Compare STRIDES PHARMA SCIENCE with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs CADILA HEALTHCARE - Comparison Results

STRIDES PHARMA SCIENCE     Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE CADILA HEALTHCARE STRIDES PHARMA SCIENCE/
CADILA HEALTHCARE
 
P/E (TTM) x 14.5 14.4 100.9% View Chart
P/BV x 0.9 2.8 30.5% View Chart
Dividend Yield % 0.6 1.5 38.8%  

Financials

 STRIDES PHARMA SCIENCE   CADILA HEALTHCARE
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
CADILA HEALTHCARE
Mar-18
STRIDES PHARMA SCIENCE/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs1,147558 205.6%   
Low Rs642362 177.6%   
Sales per share (Unadj.) Rs317.2116.3 272.8%  
Earnings per share (Unadj.) Rs7.817.9 43.9%  
Cash flow per share (Unadj.) Rs25.123.1 108.3%  
Dividends per share (Unadj.) Rs2.003.50 57.1%  
Dividend yield (eoy) %0.20.8 29.4%  
Book value per share (Unadj.) Rs274.385.4 321.1%  
Shares outstanding (eoy) m89.501,023.74 8.7%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.84.0 71.3%   
Avg P/E ratio x114.025.7 443.2%  
P/CF ratio (eoy) x35.719.9 179.6%  
Price / Book Value ratio x3.35.4 60.6%  
Dividend payout %25.519.6 130.2%   
Avg Mkt Cap Rs m80,058470,664 17.0%   
No. of employees `0002.511.8 21.2%   
Total wages/salary Rs m4,34118,545 23.4%   
Avg. sales/employee Rs Th11,325.810,072.7 112.4%   
Avg. wages/employee Rs Th1,731.41,569.1 110.3%   
Avg. net profit/employee Rs Th280.11,547.7 18.1%   
INCOME DATA
Net Sales Rs m28,394119,049 23.9%  
Other income Rs m9411,132 83.1%   
Total revenues Rs m29,334120,181 24.4%   
Gross profit Rs m3,96528,475 13.9%  
Depreciation Rs m1,5405,388 28.6%   
Interest Rs m1,962911 215.4%   
Profit before tax Rs m1,40323,308 6.0%   
Minority Interest Rs m0628 0.0%   
Prior Period Items Rs m-1680-   
Extraordinary Inc (Exp) Rs m-4360-   
Tax Rs m975,644 1.7%   
Profit after tax Rs m70218,292 3.8%  
Gross profit margin %14.023.9 58.4%  
Effective tax rate %6.924.2 28.6%   
Net profit margin %2.515.4 16.1%  
BALANCE SHEET DATA
Current assets Rs m24,83682,005 30.3%   
Current liabilities Rs m18,99360,720 31.3%   
Net working cap to sales %20.617.9 115.1%  
Current ratio x1.31.4 96.8%  
Inventory Days Days7173 97.0%  
Debtors Days Days11398 115.4%  
Net fixed assets Rs m34,28983,703 41.0%   
Share capital Rs m8951,024 87.4%   
"Free" reserves Rs m23,65186,421 27.4%   
Net worth Rs m24,54687,445 28.1%   
Long term debt Rs m15,51325,551 60.7%   
Total assets Rs m65,437180,653 36.2%  
Interest coverage x1.726.6 6.5%   
Debt to equity ratio x0.60.3 216.3%  
Sales to assets ratio x0.40.7 65.8%   
Return on assets %4.110.6 38.3%  
Return on equity %2.920.9 13.7%  
Return on capital %6.922.0 31.4%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,69742,683 36.8%   
Fx outflow Rs m73511,242 6.5%   
Net fx Rs m14,96231,441 47.6%   
CASH FLOW
From Operations Rs m1,8719,193 20.3%  
From Investments Rs m5,826-9,737 -59.8%  
From Financial Activity Rs m-10,157515 -1,972.2%  
Net Cashflow Rs m-2,615-29 9,016.9%  

Share Holding

Indian Promoters % 27.7 74.8 37.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 37.8 8.3 455.4%  
FIIs % 8.6 5.9 145.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 11.0 235.5%  
Shareholders   56,241 44,069 127.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   FDC LTD.  UNICHEM LAB  DR. REDDYS LAB  AJANTA PHARMA  ALEMBIC LTD  

Compare STRIDES PHARMA SCIENCE With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Stock Markets Remain in Green This Week: Is the Rebound Here?(Podcast)

After a long period of underperformance, stock markets traded in green territory throughout the week. So, is this is a trend reversal and is the bottom forming in the market?

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 28.9% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CADILA HEALTHCARE has posted a net profit of Rs 3 bn (down 28.9% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (4QFY19); Net Profit Down 21.0% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 21.0% YoY). Sales on the other hand came in at Rs 37 bn (up 14.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (3QFY19); Net Profit Down 3.7% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 3.7% YoY). Sales on the other hand came in at Rs 36 bn (up 9.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


Oct 18, 2019 (Close)

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE 5-YR ANALYSIS

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS